Roger R. Dmochowski, MD

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.